Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
Precigen, Inc. (NASDAQ:PGEN) is definitely on the radar of institutional investors who own 31% of the company [Yahoo! Finance]
Precigen Is Still A Buy After The Papzimeos Rally [Seeking Alpha]